

A review on the evolution of PD-1/PD-L1 immunotherapy
now

Cancer Treatment Reviews

54, 58-67

DOI: [10.1016/j.ctrv.2017.01.007](https://doi.org/10.1016/j.ctrv.2017.01.007)

Citation Report

#	ARTICLE	IF	CITATIONS
1	STAT3 Induces Immunosuppression by Upregulating PD-1/PD-L1 in HNSCC. <i>Journal of Dental Research</i> , 2017, 96, 1027-1034.	2.5	147
2	Prospects for precision therapy of bladder urothelial carcinoma. <i>Expert Review of Precision Medicine and Drug Development</i> , 2017, 2, 261-274.	0.4	1
3	The roles and applications of autoantibodies in progression, diagnosis, treatment and prognosis of human malignant tumours. <i>Autoimmunity Reviews</i> , 2017, 16, 1270-1281.	2.5	52
4	Immunotherapy of cancer: targeting cancer during active disease or during dormancy?. <i>Immunotherapy</i> , 2017, 9, 943-949.	1.0	6
5	Tumor vesical: presente y futuro. <i>Medicina Clínica</i> , 2017, 149, 449-455.	0.3	101
6	Nivolumab for the treatment of bladder cancer. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 1309-1315.	1.4	13
7	Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab. <i>Scientific Reports</i> , 2017, 7, 5532.	1.6	166
8	Bladder cancer: Present and future. <i>Medicina Clínica (English Edition)</i> , 2017, 149, 449-455.	0.1	51
9	Urothelial Bladder Cancer: An Update on Molecular Pathology with Clinical Implications. <i>European Urology Supplements</i> , 2017, 16, 272-294.	0.1	6
11	The tissue distribution and significance of B7-H4 in laryngeal carcinoma. <i>Oncotarget</i> , 2017, 8, 92227-92239.	0.8	10
12	Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives. <i>BioMed Research International</i> , 2017, 2017, 1-13.	0.9	10
13	Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy. <i>Journal of Hematology and Oncology</i> , 2017, 10, 174.	6.9	92
14	PD-L1 expression in bladder cancer and metastasis and its influence on oncologic outcome after cystectomy. <i>Oncotarget</i> , 2017, 8, 66849-66864.	0.8	47
15	Bending the Curve of Advanced Urothelial Carcinoma. <i>Journal of Oncology Practice</i> , 2017, 13, 319-320.	2.5	0
16	An <sc>FGFR</sc> 3/ <sc>MYC</sc> positive feedback loop provides new opportunities for targeted therapies in bladder cancers. <i>EMBO Molecular Medicine</i> , 2018, 10, .	3.3	54
17	Impact of bacillus Calmette–Gu–rin therapy of upper urinary tract carcinoma in situ: comparison of oncological outcomes with radical nephroureterectomy. <i>Medical Oncology</i> , 2018, 35, 41.	1.2	23
18	Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers. <i>Molecular Cancer Research</i> , 2018, 16, 805-812.	1.5	169
19	Treatment of carcinoma in situ of the urinary bladder with an alpha-emitter immunoconjugate targeting the epidermal growth factor receptor: a pilot study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1364-1371.	3.3	54

#	ARTICLE	IF	CITATIONS
20	Atezolizumab in Metastatic Urothelial Carcinoma Outside Clinical Trials: Focus on Efficacy, Safety, and Response to Subsequent Therapies. <i>Targeted Oncology</i> , 2018, 13, 353-361.	1.7	14
21	Molecular Correlates of In Vitro Responses to Dacomitinib and Afatinib in Bladder Cancer. <i>Bladder Cancer</i> , 2018, 4, 77-90.	0.2	19
22	From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?. <i>Current Oncology Reports</i> , 2018, 20, 8.	1.8	20
23	Kidney, Ureteral, and Bladder Cancer. <i>Medical Clinics of North America</i> , 2018, 102, 231-249.	1.1	11
24	Concordance study of PD-L1 expression in primary and metastatic bladder carcinomas: comparison of four commonly used antibodies and RNA expression. <i>Modern Pathology</i> , 2018, 31, 623-632.	2.9	102
25	Neurologic complications of immune checkpoint inhibitors. <i>Journal of Neuro-Oncology</i> , 2018, 137, 601-609.	1.4	126
26	Cytokine-induced killer cells as a feasible adoptive immunotherapy for the treatment of lung cancer. <i>Cell Death and Disease</i> , 2018, 9, 366.	2.7	27
27	Hypoxia gene expression signatures as predictive biomarkers for personalising radiotherapy. <i>British Journal of Radiology</i> , 2019, 92, 20180036.	1.0	24
28	Imaging response assessment of immunotherapy in patients with renal cell and urothelial carcinoma. <i>Current Opinion in Urology</i> , 2018, 28, 35-41.	0.9	12
29	Response Rate to Chemotherapy After Immune Checkpoint Inhibition in Metastatic Urothelial Cancer. <i>European Urology</i> , 2018, 73, 149-152.	0.9	93
30	Atezolizumab in urothelial bladder carcinoma. <i>Future Oncology</i> , 2018, 14, 331-341.	1.1	10
31	PD-1 blockade enhances the antitumor efficacy of GM-CSF surface-modified bladder cancer stem cells vaccine. <i>International Journal of Cancer</i> , 2018, 142, 2106-2117.	2.3	43
32	How to assess and improve health-related quality of life in bladder cancer patients. <i>Translational Andrology and Urology</i> , 2018, 7, S77-S80.	0.6	4
33	Immune checkpoint inhibitors as a real hope in advanced urothelial carcinoma. <i>Future Science OA</i> , 2018, 4, FSO341.	0.9	8
34	PD-1 Blockade Overcomes Adaptive Immune Resistance in Treatment with Anchored-GM-CSF Bladder Cancer Cells Vaccine. <i>Journal of Cancer</i> , 2018, 9, 4374-4381.	1.2	5
35	Bladder Preservation Therapy: Review of Literature and Future Directions of Trimodal Therapy. <i>Current Urology Reports</i> , 2018, 19, 108.	1.0	18
36	A Festschrift in Honor of Edward M. Messing, MD, FACS. <i>Bladder Cancer</i> , 2018, 4, S1-S43.	0.2	0
37	Trial Watch: Toll-like receptor agonists in cancer immunotherapy. <i>Oncolimmunology</i> , 2018, 7, e1526250.	2.1	172

#	ARTICLE	IF	CITATIONS
38	Bladder cancer: overview and management. Part 2: muscle-invasive and metastatic bladder cancer. <i>British Journal of Nursing</i> , 2018, 27, S8-S20.	0.3	14
39	Liver toxicity in the era of immune checkpoint inhibitors: A practical approach. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 132, 125-129.	2.0	19
40	RUSSCO-RSP comparative study of immunohistochemistry diagnostic assays for PD-L1 expression in urothelial bladder cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 473, 719-724.	1.4	27
41	Treatment Patterns and Outcomes in Stage IV Bladder Cancer in a Community Oncology Setting: 2008-2015. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e1171-e1179.	0.9	18
42	LINC00857 expression predicts and mediates the response to platinum-based chemotherapy in muscle-invasive bladder cancer. <i>Cancer Medicine</i> , 2018, 7, 3342-3350.	1.3	31
43	Self-assembly of Fluorescent Dehydroberberine Enhances Mitochondria-Dependent Antitumor Efficacy. <i>Chemistry - A European Journal</i> , 2018, 24, 9812-9819.	1.7	12
44	Personalized disease signatures through information-theoretic compaction of big cancer data. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 7694-7699.	3.3	27
45	Targeting tumor-associated acidity in cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1331-1348.	2.0	55
46	Regulation of Immune Cell Functions by Metabolic Reprogramming. <i>Journal of Immunology Research</i> , 2018, 2018, 1-12.	0.9	57
47	Endocrine, Sexual Function, and Infertility Side Effects of Immune Checkpoint Inhibitor Therapy for Genitourinary Cancers. <i>Current Urology Reports</i> , 2018, 19, 68.	1.0	12
48	The Puzzle of Predicting Response to Immune Checkpoint Blockade. <i>EBioMedicine</i> , 2018, 33, 18-19.	2.7	10
49	Profiling the Urinary Microbiota in Male Patients With Bladder Cancer in China. <i>Frontiers in Cellular and Infection Microbiology</i> , 2018, 8, 167.	1.8	148
50	Evolution of PD-1 and PD-L1 Gene and Protein Expression in Primary Tumors and Corresponding Liver Metastases of Metastatic Bladder Cancer. <i>European Urology</i> , 2018, 74, 527-529.	0.9	16
51	Safety and efficacy of durvalumab (MEDI4736) in various solid tumors. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 2085-2096.	2.0	38
52	Emerging intravesical drugs for the treatment of non muscle-invasive bladder cancer. <i>Expert Opinion on Emerging Drugs</i> , 2018, 23, 135-147.	1.0	10
53	PD-L1 Immunohistochemistry Assay Concordance in Urothelial Carcinoma of the Bladder and Hypopharyngeal Squamous Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2018, 42, 1059-1066.	2.1	79
54	Asymptomatic recurrence detection and cost-effectiveness in urothelial carcinoma. <i>Medical Oncology</i> , 2018, 35, 94.	1.2	5
55	Naturally-Occurring Canine Invasive Urothelial Carcinoma: A Model for Emerging Therapies. <i>Bladder Cancer</i> , 2018, 4, 149-159.	0.2	27

#	ARTICLE	IF	CITATIONS
56	RON is overexpressed in bladder cancer and contributes to tumorigenic phenotypes in 5637 cells. <i>Oncology Letters</i> , 2018, 15, 6547-6554.	0.8	4
57	Prognostic Value of Testing PD-L1 Expression After Radical Cystectomy in High-risk Patients. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e1015-e1024.	0.9	12
58	#Checkmate: could checkpoint inhibitors be the game changer in the fight against metastatic urothelial carcinoma?. <i>BJU International</i> , 2019, 123, 203-207.	1.3	3
59	Are mimotope vaccines a good alternative to monoclonal antibodies?. <i>Immunotherapy</i> , 2019, 11, 795-800.	1.0	9
61	Predictive biomarkers for drug response in bladder cancer. <i>International Journal of Urology</i> , 2019, 26, 1044-1053.	0.5	50
62	Cisplatin contributes to programmed death-ligand 1 expression in bladder cancer through ERK1/2-AP-1 signaling pathway. <i>Bioscience Reports</i> , 2019, 39, .	1.1	40
63	New insights in predictive determinants of the tumor immune microenvironment for immune checkpoint inhibition: a never ending story?. <i>Annals of Translational Medicine</i> , 2019, 7, S135-S135.	0.7	13
64	Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. <i>Nature Medicine</i> , 2019, 25, 1706-1714.	15.2	407
65	Evidence Builds for Tumor Mutation Burden as an Immunotherapy Biomarker. <i>Advances in Molecular Pathology</i> , 2019, 2, 177-185.	0.2	0
66	Immune Responses in Bladder Cancer-Role of Immune Cell Populations, Prognostic Factors and Therapeutic Implications. <i>Frontiers in Oncology</i> , 2019, 9, 1270.	1.3	76
68	Serum immunoglobulin levels and the risk of bladder cancer in the AMORIS Cohort. <i>Cancer Epidemiology</i> , 2019, 62, 101584.	0.8	4
69	The multifaceted immune regulation of bladder cancer. <i>Nature Reviews Urology</i> , 2019, 16, 613-630.	1.9	123
71	TRIM59: A membrane protein expressed on Bacillus Calmette-Guérin-activated macrophages that induces apoptosis of fibrosarcoma cells by direct contact. <i>Experimental Cell Research</i> , 2019, 384, 111590.	1.2	5
72	A video-based, flipped classroom, simulation curriculum for dermatologic surgery: A prospective, multi-institution study. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 1271-1276.	0.6	35
73	Combination of TMB and CNA Stratifies Prognostic and Predictive Responses to Immunotherapy Across Metastatic Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 7413-7423.	3.2	211
74	Relationship between the expression of PD-1/PD-L1 and 18F-FDG uptake in bladder cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 848-854.	3.3	60
75	Predictive Biomarkers for Muscle-invasive Bladder Cancer: The Search for the Holy Grail Continues. <i>European Urology</i> , 2019, 76, 69-70.	0.9	3
76	The Characteristics of PD-L1 Inhibitors, from Peptides to Small Molecules. <i>Molecules</i> , 2019, 24, 1940.	1.7	10

#	ARTICLE	IF	CITATIONS
77	<p>Clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis</p>. Cancer Management and Research, 2019, Volume 11, 4171-4184.	0.9	31
78	USP13 functions as a tumor suppressor by blocking the NF-κB-mediated PTEN downregulation in human bladder cancer. Journal of Experimental and Clinical Cancer Research, 2019, 38, 259.	3.5	70
79	The immune microenvironment and expression of PD-1, PRAME and MHC I in salivary duct carcinoma. Histopathology, 2019, 75, 672-682.	1.6	43
80	Formidable Scenarios in Urothelial and Variant Cancers of the Urinary Tract. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 262-275.	1.8	3
81	Conceptual Framework for Therapeutic Development Beyond Anti-PD-1/PD-L1 in Urothelial Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 284-300.	1.8	14
82	Drug strategies for bladder cancer in the elderly: is there promise for the future?. Expert Opinion on Pharmacotherapy, 2019, 20, 1387-1396.	0.9	1
83	PD-L1 expression and clinical outcomes in patients with advanced urothelial carcinoma treated with checkpoint inhibitors: A meta-analysis. Cancer Treatment Reviews, 2019, 76, 51-56.	3.4	36
84	A Combination of Positive Tumor HLA-I and Negative PD-L1 Expression Provides an Immune Rejection Mechanism in Bladder Cancer. Annals of Surgical Oncology, 2019, 26, 2631-2639.	0.7	11
85	CSTP1 inhibits IL-6 expression through targeting Akt/FoxO3a signaling pathway in bladder cancer cells. Experimental Cell Research, 2019, 380, 80-89.	1.2	11
86	Immunotherapy in non-metastatic urothelial cancer: back to the "future". Expert Opinion on Biological Therapy, 2019, 19, 685-695.	1.4	3
87	The Tumor Immune Microenvironment Drives a Prognostic Relevance That Correlates with Bladder Cancer Subtypes. Cancer Immunology Research, 2019, 7, 923-938.	1.6	148
88	<p>A meta-analysis of the efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors as treatments for metastatic bladder cancer</p>. OncoTargets and Therapy, 2019, Volume 12, 1791-1801.	1.0	20
89	Understanding Immune Evasion and Therapeutic Targeting Associated with PD-1/PD-L1 Pathway in Diffuse Large B-cell Lymphoma. International Journal of Molecular Sciences, 2019, 20, 1326.	1.8	43
90	Comment on: Relationship between the expression of PD-1/PD-L1 and 18F-FDG uptake in bladder cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1212-1213.	3.3	2
91	Precision therapy in advanced urothelial cancer. Expert Review of Precision Medicine and Drug Development, 2019, 4, 81-93.	0.4	4
92	Metformin Augments Panobinostat's Anti-Bladder Cancer Activity by Activating AMP-Activated Protein Kinase. Translational Oncology, 2019, 12, 669-682.	1.7	17
93	Bacillus Calmette-Guérin Induces PD-L1 Expression on Antigen-Presenting Cells via Autocrine and Paracrine Interleukin-STAT3 Circuits. Scientific Reports, 2019, 9, 3655.	1.6	19
94	Immune checkpoint inhibitor-related myositis associated with atezolizumab therapy. Neurology: Clinical Practice, 2019, 9, e25-e26.	0.8	10

#	ARTICLE	IF	CITATIONS
95	TYRO3 as a molecular target for growth inhibition and apoptosis induction in bladder cancer. <i>British Journal of Cancer</i> , 2019, 120, 555-564.	2.9	23
96	Additional Extension of the Mathematical Model for BCG Immunotherapy of Bladder Cancer and Its Validation by Auxiliary Tool. <i>International Journal of Nonlinear Sciences and Numerical Simulation</i> , 2019, 20, 675-689.	0.4	13
97	Protocol for phase I study of pembrolizumab in combination with Bacillus Calmette-Guérin for patients with high-risk non-muscle invasive bladder cancer. <i>BMJ Open</i> , 2019, 9, e028287.	0.8	7
98	Primary Malignant Melanoma of the Bladder Treated by Robotic Partial Cystectomy and Immunotherapy. <i>Journal of Endourology Case Reports</i> , 2019, 5, 151-153.	0.3	4
99	Single-centre Experience of Patients with Metastatic Urothelial Cancer Treated with Chemotherapy Following Immune Checkpoint Inhibition. <i>European Urology Oncology</i> , 2019, 4, 659-662.	2.6	9
100	A Multi-Institutional Study to Evaluate Automated Whole Slide Scoring of Immunohistochemistry for Assessment of Programmed Death-Ligand 1 (PD-L1) Expression in Non-Small Cell Lung Cancer. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2019, 27, 263-269.	0.6	28
101	PD-L1 Expression in Urothelial Carcinoma With Predominant or Pure Variant Histology. <i>American Journal of Surgical Pathology</i> , 2019, 43, 920-927.	2.1	59
102	WNT Signaling in Tumors: The Way to Evade Drugs and Immunity. <i>Frontiers in Immunology</i> , 2019, 10, 2854.	2.2	161
103	Altered cancer metabolism in mechanisms of immunotherapy resistance. , 2019, 195, 162-171.		97
104	Clinical and molecular characteristics of bladder urothelial carcinoma subtypes. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 9956-9963.	1.2	10
105	Combination immunotherapy with interleukin-2 surface-modified tumor cell vaccine and programmed death receptor-1 blockade against renal cell carcinoma. <i>Cancer Science</i> , 2019, 110, 31-39.	1.7	12
106	CDK4/6 Inhibitor as a Novel Therapeutic Approach for Advanced Bladder Cancer Independently of RB1 Status. <i>Clinical Cancer Research</i> , 2019, 25, 390-402.	3.2	44
107	Macrophage polarization as a novel weapon in conditioning tumor microenvironment for bladder cancer: can we turn demons into gods?. <i>Clinical and Translational Oncology</i> , 2019, 21, 391-403.	1.2	26
108	Inter- and intraobserver agreement of programmed death ligand 1 scoring in head and neck squamous cell carcinoma, urothelial carcinoma and breast carcinoma. <i>Histopathology</i> , 2020, 76, 191-200.	1.6	35
109	PET Imaging of Tumor PD-L1 Expression with a Highly Specific Nonblocking Single-Domain Antibody. <i>Journal of Nuclear Medicine</i> , 2020, 61, 117-122.	2.8	118
110	Quantitative evaluation of tumor-specific T cells in tumors and lymphoid tissues. <i>Methods in Enzymology</i> , 2020, 635, 149-166.	0.4	4
111	Assessment of the expression of the immune checkpoint molecules PD-1, CTLA4, TIM-3 and LAG-3 across different cancers in relation to treatment response, tumor-infiltrating immune cells and survival. <i>International Journal of Cancer</i> , 2020, 147, 423-439.	2.3	118
112	Intratumoral IL22-producing cells define immunoevasive subtype muscle-invasive bladder cancer with poor prognosis and superior nivolumab responses. <i>International Journal of Cancer</i> , 2020, 146, 542-552.	2.3	22

#	ARTICLE	IF	CITATIONS
113	Nanoparticle Conjugation Stabilizes and Multimerizes β -Hairpin Peptides To Effectively Target PD-1/PD-L1 β -Sheet-Rich Interfaces. <i>Journal of the American Chemical Society</i> , 2020, 142, 1832-1837.	6.6	39
114	Immune checkpoint expression, microsatellite instability, and mutational burden: Identifying immune biomarker phenotypes in uterine cancer. <i>Gynecologic Oncology</i> , 2020, 156, 393-399.	0.6	24
115	Next-Generation Sequencing Reveals Potential Predictive Biomarkers and Targets of Therapy for Urothelial Carcinoma in Situ of the Urinary Bladder. <i>American Journal of Pathology</i> , 2020, 190, 323-332.	1.9	20
116	IFI16 promotes cervical cancer progression by upregulating PD-L1 in immunomicroenvironment through STING-TBK1-NF- κ B pathway. <i>Biomedicine and Pharmacotherapy</i> , 2020, 123, 109790.	2.5	80
117	Radiation therapy before radical cystectomy combined with immunotherapy in locally advanced bladder cancer – study protocol of a prospective, single arm, multicenter phase II trial (RACE IT). <i>BMC Cancer</i> , 2020, 20, 8.	1.1	19
118	Muscle Toxicity of Drugs: When Drugs Turn Physiology into Pathophysiology. <i>Physiological Reviews</i> , 2020, 100, 633-672.	13.1	39
119	CDK12/13 inhibition induces immunogenic cell death and enhances anti-PD-1 anticancer activity in breast cancer. <i>Cancer Letters</i> , 2020, 495, 12-21.	3.2	58
120	Single-cell RNA sequencing highlights the role of inflammatory cancer-associated fibroblasts in bladder urothelial carcinoma. <i>Nature Communications</i> , 2020, 11, 5077.	5.8	281
121	Targeted Molecular Therapeutics for Bladder Cancer – A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7268.	1.8	33
122	Atezolizumab in Patients with Metastatic Urothelial Carcinoma Who Have Progressed After First-line Chemotherapy: Results of Real-life Experiences. <i>European Urology Focus</i> , 2021, 7, 1061-1066.	1.6	8
123	Quantitative Proteomics of Urinary Bladder Cancer Cell Lines Identify UAP1 as a Potential Therapeutic Target. <i>Genes</i> , 2020, 11, 763.	1.0	11
124	Research progress of PD-1/PD-L1 immunotherapy in gastrointestinal tumors. <i>Biomedicine and Pharmacotherapy</i> , 2020, 129, 110504.	2.5	26
125	Treatment Strategies and Metabolic Pathway Regulation in Urothelial Cell Carcinoma: A Comprehensive Review. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8993.	1.8	9
126	A novel risk score based on a combined signature of 10 immune system genes to predict bladder cancer prognosis. <i>International Immunopharmacology</i> , 2020, 87, 106851.	1.7	12
127	Investigating the Role of the N-Terminal Loop of PD-1 in Binding Process Between PD-1 and Nivolumab via Molecular Dynamics Simulation. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 574759.	1.6	6
128	Precision oncology in urothelial cancer. <i>ESMO Open</i> , 2020, 5, e000616.	2.0	3
129	Immune-related signature predicts the prognosis and immunotherapy benefit in bladder cancer. <i>Cancer Medicine</i> , 2020, 9, 7729-7741.	1.3	35
130	PD-1 topographically defines distinct T cell subpopulations in urothelial cell carcinoma of the bladder and predicts patient survival. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 685.e1-685.e10.	0.8	7

#	ARTICLE	IF	CITATIONS
131	Productive screening of single aptamers with ddPCR. <i>Analyst, The</i> , 2020, 145, 4130-4137.	1.7	10
132	Immune checkpoint inhibition in urothelial carcinoma. <i>Lancet, The</i> , 2020, 395, 1522-1523.	6.3	2
133	Evaluation of PD-L1 expression on circulating tumor cells (CTCs) in patients with advanced urothelial carcinoma (UC). <i>Oncoimmunology</i> , 2020, 9, 1738798.	2.1	34
134	Cuprous oxide nanoparticles trigger reactive oxygen species-induced apoptosis through activation of erk-dependent autophagy in bladder cancer. <i>Cell Death and Disease</i> , 2020, 11, 366.	2.7	33
135	Profiles of tumor-infiltrating immune cells and prognostic genes associated with the microenvironment of bladder cancer. <i>International Immunopharmacology</i> , 2020, 85, 106641.	1.7	27
136	<p>The Biogenesis, Functions, and Roles of circRNAs in Bladder Cancer</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 3673-3689.	0.9	9
137	Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 2658-2666.	0.8	186
138	Facing treatment of non-urothelial bladder cancers in the immunotherapy era. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 153, 103034.	2.0	4
139	Clinical relevance and prognostic significance of PD-1/PD-Ls in non-metastatic bladder cancer: A role for PD-L2. <i>Molecular Immunology</i> , 2020, 124, 35-41.	1.0	8
140	Harnessing cell-free DNA: plasma circulating tumour DNA for liquid biopsy in genitourinary cancers. <i>Nature Reviews Urology</i> , 2020, 17, 271-291.	1.9	32
141	<i>Kdm6a</i> Deficiency Activates Inflammatory Pathways, Promotes M2 Macrophage Polarization, and Causes Bladder Cancer in Cooperation with <i>p53</i> Dysfunction. <i>Clinical Cancer Research</i> , 2020, 26, 2065-2079.	3.2	80
142	Optimizing management of advanced urothelial carcinoma: A review of emerging therapies and biomarker-driven patient selection. <i>Canadian Urological Association Journal</i> , 2020, 14, E373-E382.	0.3	8
143	Myeloid-derived suppressor cells are essential partners for immune checkpoint inhibitors in the treatment of cisplatin-resistant bladder cancer. <i>Cancer Letters</i> , 2020, 479, 89-99.	3.2	36
144	Genome-wide association study of genetic variations associated with treatment failure after intravesical bacillus Calmette–Gu–rin therapy for non-muscle invasive bladder cancer. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1155-1163.	2.0	7
145	Predictors of use and overall survival for patients undergoing metastasectomy for bladder cancer in a national cohort. <i>International Journal of Urology</i> , 2020, 27, 736-741.	0.5	3
146	Predictive and Prognostic Role of PD-L1 in Urothelial Carcinoma Patients with Anti-PD-1/PD-L1 Therapy: A Systematic Review and Meta-Analysis. <i>Disease Markers</i> , 2020, 2020, 1-16.	0.6	11
147	Naturally-Occurring Invasive Urothelial Carcinoma in Dogs, a Unique Model to Drive Advances in Managing Muscle Invasive Bladder Cancer in Humans. <i>Frontiers in Oncology</i> , 2019, 9, 1493.	1.3	51
148	An immune relevant signature for predicting prognoses and immunotherapeutic responses in patients with muscle–invasive bladder cancer (MIBC). <i>Cancer Medicine</i> , 2020, 9, 2774-2790.	1.3	63

#	ARTICLE	IF	CITATIONS
149	Competitive glucose metabolism as a target to boost bladder cancer immunotherapy. <i>Nature Reviews Urology</i> , 2020, 17, 77-106.	1.9	91
150	<p>Resistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 83-94.	1.0	27
151	Molecular targeting of PD-1 signaling pathway as a novel therapeutic approach in HTLV-1 infection. <i>Microbial Pathogenesis</i> , 2020, 144, 104198.	1.3	7
152	Combination of novel intravesical xenogeneic urothelial cell immunotherapy and chemotherapy enhances anti-tumor efficacy in preclinical murine bladder tumor models. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1419-1433.	2.0	8
153	Metastatic sites as predictors in advanced NSCLC treated with PD-1 inhibitors: a systematic review and meta-analysis. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 1278-1287.	1.4	14
154	Sendai virus acts as a nano-booster to excite dendritic cells for enhancing the efficacy of CD47-directed immune checkpoint inhibitors against breast carcinoma. <i>Materials Chemistry Frontiers</i> , 2021, 5, 223-237.	3.2	4
155	Safety and Efficacy of Transurethral Resection of Bladder Tumor Comparing Spinal Anesthesia with Spinal Anesthesia with an Obturator Nerve Block: A Systematic Review and Meta-analysis. <i>Journal of Endourology</i> , 2021, 35, 249-258.	1.1	9
156	Future Strategies Involving Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. <i>Current Treatment Options in Oncology</i> , 2021, 22, 7.	1.3	6
157	Immune checkpoint inhibition in upper tract urothelial carcinoma. <i>World Journal of Urology</i> , 2021, 39, 1357-1367.	1.2	27
158	Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action. <i>Expert Opinion on Drug Delivery</i> , 2021, 18, 187-203.	2.4	66
159	Penile Lymphoepithelioma-Like Carcinoma: A Rare Case With PD-L1 Expression. <i>International Journal of Surgical Pathology</i> , 2021, 29, 690-692.	0.4	2
160	Immune escape mechanisms and immunotherapy of urothelial bladder cancer. <i>Journal of Clinical and Translational Research</i> , 0, , .	0.3	10
161	Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer. <i>Cancers</i> , 2021, 13, 131.	1.7	153
162	The Multiple Potential Biomarkers for Predicting Immunotherapy Responseâ€”Finding the Needle in the Haystack. <i>Cancers</i> , 2021, 13, 277.	1.7	16
163	Identification and Immunocorrelation of Prognosis-Related Genes Associated With Development of Muscle-Invasive Bladder Cancer. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 598599.	1.6	4
164	YY1 expression and PD-1 regulation in CD8 T lymphocytes. , 2021, , 289-309.		1
165	Sequential administration of anti-PD-1 and anti-Tim-3 combined with an SA-GM-CSF-anchored vaccine overcomes adaptive immune resistance to reject established bladder cancer. <i>Journal of Cancer</i> , 2021, 12, 2000-2009.	1.2	1
166	The intratumoral CXCR3 chemokine system is predictive of chemotherapy response in human bladder cancer. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	35

#	ARTICLE	IF	CITATIONS
167	Immuno-PET imaging of 68Ga-labeled nanobody Nb109 for dynamic monitoring the PD-L1 expression in cancers. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1721-1733.	2.0	41
168	<i>Stenotrophomonas maltophilia</i> inhibits host cellular immunity by activating PD-1/PD-L1 signaling pathway to induce T-cell exhaustion. <i>Molecular Immunology</i> , 2021, 130, 37-48.	1.0	3
169	PD-L1 Testing for Urothelial Carcinoma: Interchangeability, Reliability and Future Perspectives. <i>Current Drug Targets</i> , 2021, 22, 162-170.	1.0	16
170	Modulation of intratumoural myeloid cells, the hallmark of the anti-tumour efficacy induced by a triple combination: tumour-associated peptide, TLR-3 ligand and \pm PD-1. <i>British Journal of Cancer</i> , 2021, 124, 1275-1285.	2.9	5
171	Immune Checkpoint Inhibitors in Front-line Therapy for Urothelial Cancer. <i>European Urology Oncology</i> , 2021, 4, 943-947.	2.6	11
172	Therapeutic Applications of Monoclonal Antibodies in Urologic-Oncology Management - An Update. , 0, .		0
173	Remodels the Immunosuppressive Tumor Microenvironment by Combination of Bacillus Calmette-Guérin and Anti-PD-L1 in an Orthotopic Triple-Negative Breast Cancer Mouse Model. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 2247-2258.	1.0	3
174	A showcase study on personalized in silico drug response prediction based on the genetic landscape of muscle invasive bladder cancer. <i>Scientific Reports</i> , 2021, 11, 5849.	1.6	4
175	The Usefulness of Lymphadenectomy in Bladder Cancer – Current Status. <i>Medicina (Lithuania)</i> , 2021, 57, 415.	0.8	8
177	Targeting STAT3 Abrogates Tim-3 Upregulation of Adaptive Resistance to PD-1 Blockade on Regulatory T Cells of Melanoma. <i>Frontiers in Immunology</i> , 2021, 12, 654749.	2.2	14
178	PD-L1 expression in urothelial bladder cancer varies more among specimen types than between companion assays. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 479, 705-713.	1.4	1
179	A combination of ssGSEA and mass cytometry identifies immune microenvironment in muscle-invasive bladder cancer. <i>Journal of Clinical Laboratory Analysis</i> , 2021, 35, e23754.	0.9	9
180	Prognostic Impact of APOBEC3B Expression in Metastatic Urothelial Carcinoma and Its Association with Tumor-Infiltrating Cytotoxic T Cells. <i>Current Oncology</i> , 2021, 28, 1652-1662.	0.9	4
181	Curative-Intent Treatment with Durvalumab in Early-Stage Cancers. <i>Advances in Therapy</i> , 2021, 38, 2759-2778.	1.3	11
182	An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer. <i>Nature Medicine</i> , 2021, 27, 793-801.	15.2	56
183	Molecular markers of systemic therapy response in urothelial carcinoma. <i>Asian Journal of Urology</i> , 2021, 8, 376-390.	0.5	22
184	Integration of Spatial PD-L1 Expression with the Tumor Immune Microenvironment Outperforms Standard PD-L1 Scoring in Outcome Prediction of Urothelial Cancer Patients. <i>Cancers</i> , 2021, 13, 2327.	1.7	8
185	PD-L1 combined with HDAC9 is a useful prognostic predictor in hepatocellular carcinoma. <i>Translational Cancer Research</i> , 2021, 10, 2305-2317.	0.4	3

#	ARTICLE	IF	CITATIONS
186	Prognostic factors in patients with metastatic urothelial carcinoma who have treated with Atezolizumab. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1506-1513.	1.0	8
187	The Efficacy of Intra-Arterial Plus Intravesical Chemotherapy Versus Intravesical Chemotherapy Alone After Bladder-Sparing Surgery in High-Risk Bladder Cancer: A Systematic Review and Meta-Analysis of Comparative Study. <i>Frontiers in Oncology</i> , 2021, 11, 651657.	1.3	1
188	Treating Bladder Cancer: Engineering of Current and Next Generation Antibody-, Fusion Protein-, mRNA-, Cell- and Viral-Based Therapeutics. <i>Frontiers in Oncology</i> , 2021, 11, 672262.	1.3	11
189	Cost-Effectiveness of Atezolizumab Plus Chemotherapy as First-Line Therapy for Metastatic Urothelial Cancer. <i>Advances in Therapy</i> , 2021, 38, 3399-3408.	1.3	5
190	Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial. <i>European Urology Oncology</i> , 2021, 4, 456-463.	2.6	18
191	Molecular determinants of response to PD-L1 blockade across tumor types. <i>Nature Communications</i> , 2021, 12, 3969.	5.8	79
192	Combination of GP88 Expression in Tumor Cells and Tumor-Infiltrating Immune Cells Is an Independent Prognostic Factor for Bladder Cancer Patients. <i>Cells</i> , 2021, 10, 1796.	1.8	3
193	A novel immune-related gene pair prognostic signature for predicting overall survival in bladder cancer. <i>BMC Cancer</i> , 2021, 21, 810.	1.1	5
194	Role of a Modified Urothelium Immune Prognostic Index in Patients With Metastatic Urothelial Carcinoma Treated With Anti-PD-1/PD-L1-Based Therapy. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 621883.	1.6	2
195	TrendyGenes, a computational pipeline for the detection of literature trends in academia and drug discovery. <i>Scientific Reports</i> , 2021, 11, 15747.	1.6	4
196	Utility of stromal tumor infiltrating lymphocyte scoring (sTILs) for risk stratification of patients with muscle-invasive urothelial bladder cancer after radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 63.e19-63.e26.	0.8	6
197	Immune Checkpoint Inhibitors in Urothelial Bladder Cancer: State of the Art and Future Perspectives. <i>Cancers</i> , 2021, 13, 4411.	1.7	31
198	The efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors in treating advanced urothelial cancer: a meta-analysis of clinical trials. <i>Aging</i> , 2021, 13, 20468-20480.	1.4	3
199	Rab6c is a new target of miR-218 that can promote the progression of bladder cancer. <i>Molecular Medicine Reports</i> , 2021, 24, .	1.1	2
200	Assessment of immune biomarkers and establishing a triple negative phenotype in gynecologic cancers. <i>Gynecologic Oncology</i> , 2021, 163, 312-319.	0.6	9
201	p110 β PI3K as a therapeutic target of solid tumours. <i>Clinical Science</i> , 2020, 134, 1377-1397.	1.8	15
202	Cytotoxic T-cell-related gene expression signature predicts improved survival in muscle-invasive urothelial bladder cancer patients after radical cystectomy and adjuvant chemotherapy. , 2020, 8, e000162.		45
203	Oncolytic viruses: overcoming translational challenges. <i>Journal of Clinical Investigation</i> , 2019, 129, 1407-1418.	3.9	70

#	ARTICLE	IF	CITATIONS
204	Personal tumor antigens in blood malignancies: genomics-directed identification and targeting. <i>Journal of Clinical Investigation</i> , 2020, 130, 1595-1607.	3.9	10
205	Prognostic value of programmed death-ligand 1 in sarcoma: a meta-analysis. <i>Oncotarget</i> , 2017, 8, 59570-59580.	0.8	40
206	The evolving role of lymphadenectomy for bladder cancer: why, when, and how. <i>Translational Andrology and Urology</i> , 2020, 9, 3082-3093.	0.6	7
207	Bladder-sparing treatment in MIBC: where do we stand?. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2019, 71, 101-112.	3.9	17
208	Updates to Clinical Information on Anticancer Immunotherapy. <i>Korean Journal of Clinical Pharmacy</i> , 2018, 28, 65-75.	0.0	3
209	Immunoterapia z uÅ¼yciem przeciwciaÅ, monoklonalnych ukierunkowanych na szlak PD-1/PD-L1 w chorobach nowotworowych. <i>Acta Haematologica Polonica</i> , 2018, 49, 207-227.	0.1	5
210	Increased Tim-3 expression on TILs during treatment with the Anchored GM-CSF vaccine and anti-PD-1 antibodies is inversely correlated with response in prostate cancer. <i>Journal of Cancer</i> , 2020, 11, 648-656.	1.2	25
211	Programmed death ligand-1 (PD-L1) immunohistochemical assessment using the QR1 clone in muscle-invasive urothelial carcinomas: a comparison with reference clones 22C3 and SP263. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 303-313.	1.4	1
212	Adjuvant Treatment: Old and New Immunotherapy in Non-Muscle-Invasive Bladder Cancer. , 2018, , 43-47.		0
213	Resistance to Checkpoint Blockade Inhibitors and Immunomodulatory Drugs. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2019, , 155-179.	0.1	0
214	The Role of TGF-Î² and PD-L1 in the Invasion and Development of Bladder Cancer. <i>Advances in Clinical Medicine</i> , 2020, 10, 1917-1925.	0.0	0
216	ASR488, a novel small molecule, activates an mRNA binding protein, CPEB1, and inhibits the growth of bladder cancer. <i>Oncology Letters</i> , 2020, 20, 850-860.	0.8	5
217	Approaches for Personalized Drug Development in Bladder Cancer Patients. <i>The Korean Journal of Urological Oncology</i> , 2020, 18, 91-98.	0.1	0
218	Pathological roles of c-Met in bladder cancer: Association with cyclooxygenase-2, heme oxygenase-1, vascular endothelial growth factor-Â and programmed death ligand-1. <i>Oncology Letters</i> , 2020, 20, 135-144.	0.8	3
219	Immunosuppression Induced by Glutamine Deprivation Occurs via Activating PD-L1 Transcription in Bladder Cancer. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 687305.	1.6	10
220	Efficacy and safety of programmed cell death-1/programmed cell death ligand-1 inhibitors in advanced urothelial malignancy: A systematic review and meta-analysis. <i>Indian Journal of Urology</i> , 2019, 35, 101-115.	0.2	1
221	Intravesical Therapy for Non-muscle Invasive Bladder Cancer-Current and Future Options in the Age of Bacillus Calmette-Guerin Shortage. <i>Reviews in Urology</i> , 2019, 21, 145-153.	0.9	9
222	PD-1/PD-L1 pathway: current researches in cancer. <i>American Journal of Cancer Research</i> , 2020, 10, 727-742.	1.4	187

#	ARTICLE	IF	CITATIONS
223	Immune escape mechanisms and immunotherapy of urothelial bladder cancer. <i>Journal of Clinical and Translational Research</i> , 2021, 7, 485-500.	0.3	5
225	Response to first-line chemotherapy regimen is associated with efficacy of immune checkpoint blockade therapies in patients with metastatic urothelial carcinoma. <i>International Journal of Clinical Oncology</i> , 2022, 27, 585-591.	1.0	4
226	Stromal Tumor-Associated Macrophage Infiltration Predicts Poor Clinical Outcomes in Muscle-Invasive Bladder Cancer Patients. <i>Annals of Surgical Oncology</i> , 2022, , 1.	0.7	4
227	Ferroptosis Mediation Patterns Reveal Novel Tool to Implicate Immunotherapy and Multi-Omics Characteristics in Bladder Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 791630.	1.8	6
228	PD-L1 and HER2 expression in gastric adenocarcinoma and their prognostic significance. <i>Digestive and Liver Disease</i> , 2022, 54, 1419-1427.	0.4	15
229	RNA-binding proteins: Underestimated contributors in tumorigenesis. <i>Seminars in Cancer Biology</i> , 2022, 86, 431-444.	4.3	14
230	Comprehensive Analysis of N6-methyladenosine Modification Patterns Associated With Multiomic Characteristics of Bladder Cancer. <i>Frontiers in Medicine</i> , 2021, 8, 757432.	1.2	5
231	Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial. <i>Nature Medicine</i> , 2021, 27, 2200-2211.	15.2	65
232	Proteasomal Processing Immune Escape Mechanisms in Platinum-Treated Advanced Bladder Cancer. <i>Genes</i> , 2022, 13, 422.	1.0	2
233	De Ritis Ratio, Neutrophil-to-Lymphocyte Ratio, and Albumin Are Significant Prognostic Factors for Survival Even After Adjusted by the Treatment Duration in Metastatic Kidney and Bladder Cancer Treated With Immune-Checkpoint Inhibitors. <i>The Korean Journal of Urological Oncology</i> , 2022, 20, 25-33.	0.1	0
234	Cell death-induced immunogenicity enhances chemoimmunotherapeutic response by converting immune-excluded into T-cell inflamed bladder tumors. <i>Nature Communications</i> , 2022, 13, 1487.	5.8	17
235	The Evolution of Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. <i>Cancers</i> , 2022, 14, 1640.	1.7	3
236	96DRA-Urine: A high throughput sample preparation method for urinary proteome analysis. <i>Journal of Proteomics</i> , 2022, 257, 104529.	1.2	2
237	Improving the role of immune checkpoint inhibitors in the management of advanced urothelial carcinoma, where do we stand?. <i>Translational Oncology</i> , 2022, 19, 101387.	1.7	2
238	Cost-Effectiveness of Immune Checkpoint Inhibitors in Urothelial Carcinoma—A Review. <i>Cancers</i> , 2022, 14, 73.	1.7	3
239	Tetrahedral DNA nanostructures synergize with MnO ₂ to enhance antitumor immunity via promoting STING activation and M1 polarization. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 2494-2505.	5.7	11
240	Identification of an immune gene-associated prognostic signature in patients with bladder cancer. <i>Cancer Gene Therapy</i> , 2022, 29, 494-504.	2.2	6
241	Expression and Prognostic Implication of PD-L1 in Patients with Urothelial Carcinoma with Variant Histology (Squamous Differentiation or Micropapillary) Undergoing Radical Cystectomy. <i>Biomedicines</i> , 2022, 10, 910.	1.4	2

#	ARTICLE	IF	CITATIONS
242	Pyroptosis-Related Signature Predicts Prognosis and Immunotherapy Efficacy in Muscle-Invasive Bladder Cancer. <i>Frontiers in Immunology</i> , 2022, 13, 782982.	2.2	19
258	PD-L1 Expression in Bladder Cancer and Correlation with Tumor Grade, Stage and Outcome. <i>Oman Medical Journal</i> , 0, , .	0.3	1
260	Optochemical Control of Immune Checkpoint Blockade via Light-Triggered PD-L1 Dimerization. <i>Advanced NanoBiomed Research</i> , 2022, 2, .	1.7	4
261	A rare and complete response to combination therapy with radiation and nivolumab in a patient with metastatic urothelial cancer. <i>BMJ Case Reports</i> , 2022, 15, e246653.	0.2	2
262	A Novel Chinese Herbal and Corresponding Chemical Formula for Cancer Treatment by Targeting Tumor Maintenance, Progression, and Metastasis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	0
263	Immunological Characteristics of Alternative Splicing Profiles Related to Prognosis in Bladder Cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	11
264	Comprehensive analysis of the PD-L1 and immune infiltrates of N6-methyladenosine related long non-coding RNAs in bladder cancer. <i>Scientific Reports</i> , 2022, 12, .	1.6	3
265	Computational discovery of small drug-like compounds as potential inhibitors of PD-1/PD-L1 interactions. <i>Journal of Biomolecular Structure and Dynamics</i> , 0, , 1-17.	2.0	1
266	Mass cytometry reveals immune atlas of urothelial carcinoma. <i>BMC Cancer</i> , 2022, 22, .	1.1	5
267	Correlation between the Treg/Th17 Index and the Efficacy of PD-1 Monoclonal Antibody in Patients with Advanced Non-Small-Cell Lung Cancer Complicated with Chronic Obstructive Pulmonary Disease. <i>Computational and Mathematical Methods in Medicine</i> , 2022, 2022, 1-11.	0.7	0
268	Autophagy blockade potentiates cancer-associated immunosuppression through programmed death ligand-1 upregulation in bladder cancer. <i>Journal of Cellular Physiology</i> , 2022, 237, 3587-3597.	2.0	8
269	PD-L1 expression on circulating tumor cells can be a predictive biomarker to PD-1 inhibitors combined with radiotherapy and antiangiogenic therapy in advanced hepatocellular carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	22
270	Multicomponent siRNA/miRNA-loaded modified mesoporous silica nanoparticles targeted bladder cancer for a highly effective combination therapy. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	21
271	An enhancer RNA-based risk model for prediction of bladder cancer prognosis. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	0
272	The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	83
273	A lipid metabolism-related risk signature for patients with gliomas constructed with TCGA and CGGA data. <i>Medicine (United States)</i> , 2022, 101, e30501.	0.4	0
274	Prognostic Signature Development on the Basis of Macrophage Phagocytosis-Mediated Oxidative Phosphorylation in Bladder Cancer. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-39.	1.9	2
276	Potential of the therapeutic effect of intravesical BCG through synthetic and biogenic selenium nanoparticles in a nitrosamine-induced bladder cancer mouse model. <i>Advances in Cancer Biology Metastasis</i> , 2022, 6, 100061.	1.1	1

#	ARTICLE	IF	CITATIONS
277	A Novel m7G-Related Genes-Based Signature with Prognostic Value and Predictive Ability to Select Patients Responsive to Personalized Treatment Strategies in Bladder Cancer. <i>Cancers</i> , 2022, 14, 5346.	1.7	5
278	Immune Checkpoint Inhibitors in Urothelial Carcinoma (Literature Review). <i>Kreativna i Hirurģi i Onkologi</i> , 2022, 12, 205-216.	0.1	0
280	BCG downregulates PD1 and PD-L1 expression in bladder cancer cells co-cultivated with peripheral blood mononuclear cells. <i>Surgical and Experimental Pathology</i> , 2022, 5, .	0.2	1
281	N6-methyladenosine-related lncRNAs in combination with computational histopathology and radiomics predict the prognosis of bladder cancer. <i>Translational Oncology</i> , 2023, 27, 101581.	1.7	3
282	Roles of m ⁶ A modification in oral cancer (Review). <i>International Journal of Oncology</i> , 2022, 62, .	1.4	2
283	Programmed death ligand 1 and tumor-infiltrating CD8+ T lymphocytes are associated with the clinical features in meningioma. <i>BMC Cancer</i> , 2022, 22, .	1.1	2
284	Landscape of the intratumoral microenvironment in bladder cancer: Implications for prognosis and immunotherapy. <i>Computational and Structural Biotechnology Journal</i> , 2023, 21, 74-85.	1.9	1
285	Urine PD-L1 is a tumor tissue candidate substitute and is associated with poor survival in muscle-invasive bladder cancer patients. <i>International Immunopharmacology</i> , 2023, 114, 109535.	1.7	0
286	Enhanced anti-tumor immunity of vaccine combined with anti-PD-1 antibody in a murine bladder cancer model. <i>Investigative and Clinical Urology</i> , 2023, 64, 74.	1.0	3
287	Gallium-68 labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics. <i>Clinical Cancer Research</i> , 2023, 29, 581-591.	3.2	8
288	SN ³⁸ , an active metabolite of irinotecan, enhances anti-PD1 treatment efficacy in head and neck squamous cell carcinoma. <i>Journal of Pathology</i> , 0, , .	2.1	1
289	Nomogram to predict overall survival in patients with primary bladder neuroendocrine carcinoma: a population-based study. <i>Future Oncology</i> , 0, , .	1.1	0
290	Inhibition of bladder cancer growth with homoharringtonine by inactivating integrin $\alpha 5/\beta 1$ -FAK/Src axis: A novel strategy for drug application. <i>Pharmacological Research</i> , 2023, 188, 106654.	3.1	8
291	The Immune Landscape and Therapy of Upper Tract Urothelial Carcinoma. , 2023, , .		0
292	Stelletin B Induces Cell Death in Bladder Cancer Via Activating the Autophagy/DAPK2/Apoptosis Signaling Cascade. <i>Marine Drugs</i> , 2023, 21, 73.	2.2	6
293	Identification of tumor antigens and immune landscapes for bladder urothelial carcinoma mRNA vaccine. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	4
294	Peripheral PD-1 and Tim-3 percentages are associated with primary sites and pathological types of peritoneal neoplasms. <i>BMC Cancer</i> , 2023, 23, .	1.1	2
295	Advances and Perspectives in Urinary Bladder Cancer Nanotherapy. <i>European Medical Journal Urology</i> , 0, , 52-61.	0.0	0

#	ARTICLE	IF	CITATIONS
296	Crosstalk of disulfidptosis-related subtypes, establishment of a prognostic signature and immune infiltration characteristics in bladder cancer based on a machine learning survival framework. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	53
307	Bioinformatics in urology â€” molecular characterization of pathophysiology and response to treatment. <i>Nature Reviews Urology</i> , 0, , .	1.9	0